Enterprise Value
362.4M
Cash
288.4M
Avg Qtr Burn
N/A
Short % of Float
21.16%
Insider Ownership
8.50%
Institutional Own.
99.41%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ARCT-154 Details COVID-19 | NDA Acceptance for review | |
ARCT-810 Details Urea cycle disorder, Ornithine transcarbmylase deficiency | Phase 2 Data readout | |
ARCT-2138 Details Influenza | Phase 1b Data readout | |
ARCT-032 Details Lung disease, Cystic fibrosis | Phase 1b Update | |
ARCT-021 Details COVID-19 | Failed Discontinued |